Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

646
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
646
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

1.0K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.0K
Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

1.1K
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
1.1K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

319
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
319
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

1.1K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.1K
Anxiolytic Drugs: Benzodiazepines and Buspirone01:29

Anxiolytic Drugs: Benzodiazepines and Buspirone

2.8K
Benzodiazepines are a class of anxiolytic drugs known for their rapid efficacy and high therapeutic-to-lethal dose ratio, but with a potential risk of drug dependence. These drugs are lipophilic, allowing for rapid absorption after oral administration, eventually reaching the central nervous system (CNS). Once in the CNS, benzodiazepines bind to the allosteric site of the GABAA receptor. This binding enhances the inhibitory effects of the neurotransmitter GABA. By doing so, they prevent...
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The association between mental health disorders and allergic reactions: a multicenter retrospective analysis.

Journal of psychiatric research·2026
Same author

Traditional Uses of <i>Thymus</i> Species in the Balkans: Ethnopharmacology, Food, and Cultural Heritage.

Life (Basel, Switzerland)·2026
Same author

Green Materials for Cement Clinker: Assessing Alternative Raw Material Potential.

Materials (Basel, Switzerland)·2026
Same author

Somatic Embryogenesis of Selected <i>Pinus</i> Species: Developmental Stages of <i>Pinus peuce</i> and <i>Pinus heldreichii</i>.

Plants (Basel, Switzerland)·2026
Same author

Effect of preoperative cognitive and physical optimization in the prevention of postoperative cognitive deficit in elderly patients with lung resection - cognition trial.

Trials·2025
Same author

Pharmacist-led medication safety interventions to reduce long-acting injectable-related medication incidents during community-to-inpatient transitions of care.

The mental health clinician·2025

Related Experiment Video

Updated: Mar 7, 2026

Author Spotlight: Studying Drug Impacts on Brain Signals Using Dual LFP Recording Protocol in Mice
04:44

Author Spotlight: Studying Drug Impacts on Brain Signals Using Dual LFP Recording Protocol in Mice

Published on: February 16, 2024

2.3K

Brexpiprazole.

Marija Markovic1, Alyssa Gallipani2, Krina H Patel1,3

  • 11 Rutgers, The State University of New Jersey, Piscataway Township, NJ, USA.

The Annals of Pharmacotherapy
|February 24, 2017
PubMed
Summary
This summary is machine-generated.

Brexpiprazole effectively treats schizophrenia and major depressive disorder (MDD) as an add-on therapy. Clinical trials show efficacy at specific dosages, with advantages including once-daily dosing and good tolerability.

Keywords:
antipsychoticbrexpiprazolemajor depressive disorderschizophrenia

More Related Videos

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
10:51

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists

Published on: November 15, 2013

13.2K
Self-Administration of Drugs in Mouse Models of Feeding and Obesity
03:37

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Published on: June 8, 2021

5.2K

Related Experiment Videos

Last Updated: Mar 7, 2026

Author Spotlight: Studying Drug Impacts on Brain Signals Using Dual LFP Recording Protocol in Mice
04:44

Author Spotlight: Studying Drug Impacts on Brain Signals Using Dual LFP Recording Protocol in Mice

Published on: February 16, 2024

2.3K
Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
10:51

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists

Published on: November 15, 2013

13.2K
Self-Administration of Drugs in Mouse Models of Feeding and Obesity
03:37

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Published on: June 8, 2021

5.2K

Area of Science:

  • Psychiatry
  • Pharmacology
  • Clinical Therapeutics

Background:

  • Schizophrenia and major depressive disorder (MDD) are significant mental health conditions requiring effective treatment options.
  • Brexpiprazole is a novel pharmacological agent investigated for these indications.

Purpose of the Study:

  • To review the pharmacology and clinical data of brexpiprazole for schizophrenia and MDD.
  • Evaluate the efficacy and safety of brexpiprazole based on available clinical trial data.

Main Methods:

  • Literature search of PubMed and MEDLINE for brexpiprazole studies up to September 2016.
  • Inclusion of Phase 3 human clinical trial data and manufacturer's product labeling.
  • Incorporation of in vitro and animal data for pharmacology and pharmacokinetics.

Main Results:

  • Four Phase 3 trials assessed brexpiprazole in schizophrenia and as an adjunct for MDD.
  • Brexpiprazole demonstrated superiority over placebo in schizophrenia (4 mg) and MDD (2-3 mg) adjunct therapy.
  • Common adverse effects included akathisia and weight gain.

Conclusions:

  • Brexpiprazole is effective for schizophrenia (2-4 mg/d) and as an adjunct for MDD (2-3 mg/d).
  • Advantages include once-daily dosing, good tolerability, and no impact on sexual function.
  • Limitations include a lack of long-term safety data and potential cost concerns.